El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

256548.pdf (3.02 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-08-01

Llicència de publicació

cc-by (c) Roldán, Fiorella L. et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/209242

Prognostic Gene Expression-Based Signature in Clear-Cell Renal Cell Carcinoma

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/cancers14153754

Resum

The inaccuracy of the current prognostic algorithms and the potential changes in the therapeutic management of localized ccRCC demands the development of an improved prognostic model for these patients. To this end, we analyzed whole-transcriptome profiling of 26 tissue samples from progressive and non-progressive ccRCCs using Illumina Hi-seq 4000. Differentially expressed genes (DEG) were intersected with the RNA-sequencing data from the TCGA. The overlapping genes were used for further analysis. A total of 132 genes were found to be prognosis-related genes. LASSO regression enabled the development of the best prognostic six-gene panel. Cox regression analyses were performed to identify independent clinical prognostic parameters to construct a combined nomogram which includes the expression of CERCAM, MIA2, HS6ST2, ONECUT2, SOX12, TMEM132A, pT stage, tumor size and ISUP grade. A risk score generated using this model effectively stratified patients at higher risk of disease progression (HR 10.79; p < 0.001) and cancer-specific death (HR 19.27; p < 0.001). It correlated with the clinicopathological variables, enabling us to discriminate a subset of patients at higher risk of progression within the Stage, Size, Grade and Necrosis score (SSIGN) risk groups, pT and ISUP grade. In summary, a gene expression-based prognostic signature was successfully developed providing a more precise assessment of the individual risk of progression.

Matèries

Genètica, Marcadors genètics, Medicina personalitzada, Càncer de ronyó, Pronòstic mèdic

Matèries (anglès)

Genetics, Genetic markers, Personalized medicine, Renal cancer, Prognosis

Citació

Col·leccions

Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ROLDÁN, Fiorella l., IZQUIERDO REYES, Laura, INGELMO-TORRES, Mercedes, LOZANO SALVATELLA, Juan josé, CARRASCO, Raquel, CUÑADO, Alexandra, REIG TORRAS, Oscar, MENGUAL BRICHS, Lourdes, ALCARAZ ASENSIO, Antonio. Prognostic Gene Expression-Based Signature in Clear-Cell Renal Cell Carcinoma. _Cancers_. 2022. Vol. 14, núm. 15. [consulta: 7 de gener de 2026]. ISSN: 2072-6694. [Disponible a: https://hdl.handle.net/2445/209242]

Exportar metadades

JSON - METS

Compartir registre